DAX23.239 +0,6%Est505.529 +0,3%MSCI World4.343 -0,1%Top 10 Crypto11,91 +5,5%Nas22.859 +2,6%Bitcoin76.896 +2,0%Euro1,1528 +0,1%Öl63,37 +1,4%Gold4.124 +1,4%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 Bayer BAY001 NVIDIA 918422 Novo Nordisk A3EU6F RENK RENK73 DroneShield A2DMAA Siemens Energy ENER6Y Lufthansa 823212 Alphabet A (ex Google) A14Y6F Deutsche Telekom 555750 HENSOLDT HAG000 TKMS thyssenkrupp Marine Systems TKMS00 Amazon 906866 BASF BASF11 Allianz 840400
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX letztlich höher -- Novo Nordisk scheitert bei Alzheimer-Studie -- Deutsche Telekom, Alphabet, TKMS, D-Wave, DroneShield, Siemens Energy, Rheinmetall & Co., DHL, Bayer, Lufthansa, NEL im Fokus
Top News
Wie viel eine Ethereum Classic-Investition von vor 1 Jahr gekostet hätte Wie viel eine Ethereum Classic-Investition von vor 1 Jahr gekostet hätte
So lohnend wäre ein Einstieg in Bitcoin Cash von vor 1 Jahr gewesen So lohnend wäre ein Einstieg in Bitcoin Cash von vor 1 Jahr gewesen
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Johnson Johnson Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
178,66 EUR +0,48 EUR +0,27 %
FSE
204,80 USD +0,72 USD +0,35 %
BTT
Johnson Johnson jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.426,55 Mrd. EUR

KGV24,98Div. Rendite3,40%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN853260

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS4781601046

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolJNJ

Johnson Johnson Aktien News

DatumMeistgelesen
PR NewswireNew long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis
EN, Johnson & JohnsonNew long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis
EN, Johnson & JohnsonJohnson & Johnson set to revolutionize the treatment of cancer with the acquisition of Halda Therapeutics
Wer­bungJohnson Johnson-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
MarketWatchL.A. Lakers coach JJ Redick lists his Brooklyn ‘trophy’ penthouse for $6.2 million
EN, Johnson & JohnsonDARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma
PR NewswireDARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma
EN, Johnson & JohnsonFDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder
PR NewswireFDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder
EN, Johnson & JohnsonJohnson & Johnson reinforces its leadership in hematology at ASH 2025 unveiling new paradigm-shifting research
EN, Johnson & JohnsonJohnson & Johnson One Year Data Demonstrate Durable Performance and Safety of the Shockwave Javelin Peripheral IVL Catheter in Late-Breaking Presentation at VIVA 2025
EN, Johnson & JohnsonJohnson & Johnson Confirms Durability of IVL in Complex, Below-the-Knee Anatomy in Late-Breaking Presentation at VIVA 2025
EN, Johnson & JohnsonJohnson & Johnson Showcases Latest Advancements in Pulsed Field Ablation with Multiple Clinical and Real-world Studies at APHRS and JPHRS
EN, Johnson & JohnsonJohnson & Johnson submits application to U.S. FDA for STELARA® (ustekinumab) in the treatment of pediatric ulcerative colitis
PR NewswireJohnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting
EN, Johnson & JohnsonJohnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting
EN, Johnson & JohnsonJohnson & Johnson to Advance Robotics Development with NVIDIA Isaac for Healthcare
PR NewswireNew study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile
EN, Johnson & JohnsonJohnson & Johnson Advances Polyphonic™ AI Fund for Surgery for Data-Driven Healthcare
EN, Johnson & JohnsonNew study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile
PR NewswireTREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years
PR NewswireIcotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis
EN, Johnson & JohnsonIcotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis
EN, Johnson & JohnsonTREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn’s disease at two years
PR NewswirePublished in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies
EN, Johnson & JohnsonPublished in The Lancet: Nipocalimab significantly decreased Sjögren’s disease (SjD) activity and severity through substantial reduction in Sjögren’s-related autoantibodies
EN, Johnson & JohnsonJohnson & Johnson MedTech Highlights Newest Impella Heart Pump and Long-Term Survival Data at TCT 2025
EN, Johnson & JohnsonIcotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis
PR NewswireIcotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis

Johnson Johnson News

Johnson Johnson News: auf dieser Seite finden Sie alle Johnson Johnson News und Nachrichten zur Johnson Johnson Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Johnson Johnson News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Johnson Johnson News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.